Results 151 to 160 of about 12,232 (185)
Current and future role of PCSK9 inhibitors in ASCVD prevention. [PDF]
Future CardiolGreco A, Capodanno D.
europepmc +1 more source
Surface-modified extracellular vesicles take their chance in the big PCSK9 inhibitors' race. [PDF]
Mol TherBen-Aicha S, Emanueli C.
europepmc +1 more source
Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases. [PDF]
BiomedicinesLi Z +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita Agarwala +2 more
exaly +4 more sources
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita Agarwala +2 more
exaly +4 more sources
PCSK9 inhibitors for treating hypercholesterolemia
Expert Opinion on Pharmacotherapy, 2020Introduction: Scientific evidence on subjects treated with statin or other lipid-lowering treatments has established that treatments aiming to lower low-density lipoprotein cholesterol (LDL-C) can reduce atherosclerosis. PCSK9 inhibitors (PCSK9-i), thanks to their efficacy in reducing LDL-C constitute a further step in the treatment of dyslipidemia and
Andrea Pasta +2 more
exaly +3 more sources
Current Opinion in Lipidology, 2013
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
To summarize the therapeutic strategies to inhibit PCSK9 and to describe the main results obtained in phase I and II trials with monoclonal antibodies targeting PCSK9.Among the various approaches for PCSK9 inhibition, human data are only available for inhibition of PCSK9 binding to LDL receptor by monoclonal antibodies.
openaire +2 more sources
PCSK9 inhibitors and cardiovascular outcomes
Expert Opinion on Biological Therapy, 2019Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering drugs are beneficial for the primary and secondary prevention of cardiovascular (CV) disease.
Daniel, Steffens +6 more
openaire +2 more sources
Lipid lowering with PCSK9 inhibitors
Nature Reviews Cardiology, 2014Statins are the most-effective therapy currently available for lowering the LDL-cholesterol (LDL-C) level and preventing cardiovascular events. Additional therapies are necessary for patients who cannot reach the target LDL-C level when taking the maximum-tolerated dose of a statin.
Razvan T, Dadu, Christie M, Ballantyne
openaire +2 more sources